## BACKGROUND. Tamoxifen sensitizes cancer cells to chemotherapeutic agents. High dose tamoxifen has been tested in the treatment of patients with melanoma and other cancers. The authors conducted a Phase II study of high dose tamoxifen plus cisplatin and etoposide for patients with advanced, inop
Experience with tamoxifen/etoposide in the treatment of a child with myxopapillary ependymoma
โ Scribed by Madden, Jennifer R. ;Fenton, Laura Z. ;Weil, Michael ;Winston, Ken R. ;Partington, Michael ;Foreman, Nicholas K.
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 144 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0098-1532
- DOI
- 10.1002/mpo.1168
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The case being presented is that of a 6-year-old boy with craniopharyngioma. The discussion centers on the controversy regarding the optimal therapy for craniopharyngioma: surgery alone; radiotherapy alone, or combined therapy using both surgery and radiation. This patient was treated with biopsy an
The patient to be discussed today is an 8 1 โ2-year-old girl. She was referred to us in February 1994 when 4 years old because of recurrent severe headaches, paraesthesias of the extremities, erythromelalgia, abdominal pain, and a platelet count of between 1,300 and 1,500 ร 10 9 /L. Physical examina
## BACKGROUND. Based on previous data demonstrating a potentially synergistic interaction between tamoxifen and cisplatin in metastatic melanoma therapy, a Phase I1 study was performed to assess the activity of tamoxifen, etoposide, mitoxantrone, and cisplatin (TEMP) in patients with metastatic br
A %year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporooccipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green C